• ATL (ADVANCED TECHNOLOGIES LABORATORY), sarl. was founded by Dr. Moncef BenKhalifa in Paris In 1998. ATL started  to provide consultancy, technology transfer and training to IVF, andrology, genetics, and molecular biology laboratories worldwide. ATL geographically extended its services to Europe as well as the Middle East and North Africa.
  • In 2002, ATL established and validated a new R&D facility for “Genomic Research”.
  • In 2003, ATL and a Turkish biotechnology company, Medimiks, decided to merge their companies and hence transferred shares to each other: These companies began working together in the field of biotechnology and provide advanced technology and complete product mix to IVF and genetics laboratories. The reputation of their services is based upon the quality of their know-how; from production through to sales and after sales technical support.
  • In 2006, Medimiks’s microarray development project was supported by TUBITAK-TEYDEB (The Scientific & Technological Research Council of Turkey - Technology and Innovation Funding Programs Directorate). With the partnership of  Medimiks, a new technopark company, OKSANTE Inc. was established  in order to do research for the development  of  oxidative stress analysis methods and antioxidants.
  •  In 2007, ATL-Medimiks transferred its know-how in microarray technology to Medimiks and participated in Medimiks’ EUREKA project titled “Development and commercialization of microarray for molecular karyotype by CGH Array”: This R&D project was completed in 2009.
  •  Starting in 2010, ATL-Medimiks changed its focus to “Transcriptomics”, which helps to understand the genome expression profile on oocyte and sperm competency in severe infertility cases which is around 17% of the all infertile cases
  • In 2019, ATL also started to provide “personalized medicine” tests with the clinical support of a Turkish organization, GENITARA, Personalized Medicine Services (